Risedronate did not block the maximal anabolic effect of PTH in aged rats

Bone

Volumn 41, Issue 5, 2007, Pages 813-819

  Yao, Wei ^a   Su, Ming ^a   Zhang, Qing ^a   Tian, Xiaoyan ^a   Setterberg, Rebecca B ^a   Blanton, Cindy ^b   Lundy, Mark W ^b   Phipps, Roger ^b   Jee, Webster S S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bone morphology; PTH; Risedronate; Withdrawal

Indexed keywords

PARATHYROID HORMONE; RISEDRONIC ACID;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE TURNOVER; CELL MATURATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSSIFICATION; RAT; TIBIA SHAFT; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; AGE FACTORS; ANABOLIC AGENTS; ANIMALS; ETIDRONIC ACID; FEMALE; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35348885488     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.07.005     Document Type: Article

References (41)

1. Gilchrist N. Antiresorptive agents, raloxifene, and PHARMAC. N Z Med J 119 1230 (2006) U1885
2. Cranney A., and Adachi J.D. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 28 8 (2005) 721-730
3. Pande I., and Hosking D.J. Oral antiresorptive therapy. Curr Rheumatol Rep 7 1 (2005) 71-77
4. Babat L.B., McLain R., Milks R., Ferrara L., and Sohn M.J. The effects of the antiresorptive agents calcitonin and pamidronate on spine fusion in a rabbit model. Spine J 5 5 (2005) 542-547
5. Papapoulos S.E. Who will benefit from antiresorptive treatment (bisphosphonates)?. Best Pract Res Clin Rheumatol 19 6 (2005) 965-973
6. Bilezikian J.P., Rubin M.R., and Finkelstein J.S. Parathyroid hormone as an anabolic therapy for women and men. J Endocrinol Invest 28 8 Suppl (2005) 41-49
7. Cosman F. Anabolic therapy for osteoporosis: parathyroid hormone. Curr Rheumatol Rep 8 1 (2006) 63-69
8. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26 5 (2005) 688-703
9. Seeman E., and Delmas P.D. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 12 7 (2001) 281-283
10. Shen V., Birchman R., Xu R., Otter M., Wu D., Lindsay R., et al. Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. J Clin Invest 96 5 (1995) 2331-2338
11. Hodsman A.B., Drost D., Fraher L.J., Holdsworth D., Thornton M., Hock J., et al. The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res 14 5 (1999) 675-679
12. Ma Y.L., Bryant H.U., Zeng Q., Schmidt A., Hoover J., Cole H.W., et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144 5 (2003) 2008-2015
13. Zhou H., Shen V., Dempster D.W., and Lindsay R. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J Bone Miner Res 16 7 (2001) 1300-1307
14. Cosman F., Shen V., Xie F., Seibel M., Ratcliffe A., and Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med 118 5 (1993) 337-343
15. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16 10 (2001) 1846-1853
16. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350 9077 (1997) 550-555
17. Reeve J., Mitchell A., Tellez M., Hulme P., Green J.R., Wardley-Smith B., et al. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab 19 2 (2001) 102-114
18. Lane N., and Morris S. New perspectives on parathyroid hormone therapy. Curr Opin Rheumatol 17 4 (2005) 467-474
19. Gasser J.A., Kneissel M., Thomsen J.S., and Mosekilde L. PTH and interactions with bisphosphonates. J Musculoskel Neuronal Interact 1 (2000) 53-56
20. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353 6 (2005) 555-565
21. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 13 (2003) 1207-1215
22. Cosman F., Nieves J., Zion M., Woelfert L., Luckey M., and Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353 6 (2005) 566-575
23. Cosman F., Nieves J., Woelfert L., Shen V., and Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13 6 (1998) 1051-1055
24. Li M., Mosekilde L., Sogaard C.H., Thomsen J.S., and Wronski T.J. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16 6 (1995) 629-635
25. Bonnick S., Saag K.G., Kiel D.P., McClung M., Hochberg M., Burnett S.A., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years 1. J Clin Endocrinol Metab 91 7 (2006) 2631-2637
26. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study 3. J Bone Miner Res 20 1 (2005) 141-151
27. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 6 (1987) 595-610
28. Ma Y., Jee W.S., Chen Y., Gasser J., Ke H.Z., Li X.J., et al. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. J Bone Miner Res 10 11 (1995) 1726-1734
29. Rhee Y., Won Y.Y., Baek M.H., and Lim S.K. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. J Bone Miner Res 19 6 (2004) 931-937
30. Hodsman A.B., Fraher L.J., Watson P.H., Ostbye T., Stitt L.W., Adachi J.D., et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82 2 (1997) 620-628
31. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85 6 (2000) 2129-2134
32. Garces C., and Garcia L.E. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 54 1 (2006) 47-54
33. Sowa H., Kaji H., Iu M.F., Tsukamoto T., Sugimoto T., and Chihara K. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J Biol Chem 278 52 (2003) 52240-52252
34. Dobnig H., and Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 8 (1995) 3632-3638
35. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 11 (2005) 4577-4583
36. Keller H., and Kneissel M. SOST is a target gene for PTH in bone. Bone 37 2 (2005) 148-158
37. Hurley M., Yao W., and Lane N.E. Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Osteoporos Int 16 12 (2005) 2080-2084
38. Hurley M.M., Okada Y., Xiao L., Tanaka Y., Ito M., Okimoto N., et al. Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2+/- mice. Biochem Biophys Res Commun 341 4 (2006) 989-994
39. Hurley M.M., Tetradis S., Huang Y.F., Hock J., Kream B.E., Raisz L.G., et al. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J Bone Miner Res 14 5 (1999) 776-783
40. Lecart M.P., Bruyere O., and Reginster J.Y. Combination/sequential therapy in osteoporosis. Curr Osteoporos Rep 2 4 (2004) 123-130
41. Fuchs R.K., Phipps R.J., and Burr D.B. Trabecular bone turnover is reestablished sooner in ovariectomized rats after withdrawal of treatment with risedronate vs alendronate. Bone 38 (2006) S50